Genetic markers for prediction of treatment outcomes in ovarian cancer

Related Experiment Video

Updated: Apr 27, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

E Caiola1, M Broggini1, M Marabese1

  • 1Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.

The Pharmacogenomics Journal
|July 9, 2014
PubMed

Insights

Genetic variations influence how epithelial ovarian cancer (EOC) patients respond to chemotherapy. Identifying specific single nucleotide polymorphisms (SNPs) could help predict treatment outcomes and personalize therapy for better results.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacogenomics

Background:

  • Drug resistance in epithelial ovarian cancer (EOC) poses a significant challenge to treatment efficacy.
  • Inter-individual genomic heterogeneity may contribute to variable responses to chemotherapy.
  • Genes involved in platinum and taxane metabolism and extrusion are potential targets for understanding drug response.

Purpose of the Study:

  • To review candidate genetic markers, specifically single nucleotide polymorphisms (SNPs), for predicting treatment outcomes in ovarian cancer.
  • To explore the potential of genetic variants in optimizing patient stratification and therapy selection.

Main Methods:

  • Literature review of studies investigating the association between SNPs and chemotherapy response in ovarian cancer.
  • Analysis of genetic markers related to platinum-based drugs inactivation and taxane metabolism/extrusion.

Main Results:

  • Several studies have detected associations between SNPs and chemotherapy response in ovarian cancer.
  • However, results are often conflicting, preventing clear conclusions.
  • The role of specific genetic variants in determining treatment response and clinical outcome requires further clarification.

Conclusions:

  • Clarifying the role of genetic variants in EOC chemotherapy response is crucial for patient stratification.
  • Personalized therapeutic strategies based on genetic profiles could optimize treatment outcomes.
  • Further research is needed to resolve conflicting results and establish reliable genetic markers for ovarian cancer therapy.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.3K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81